Panacea Biotec Ltd has informed BSE the Company has entered into an agreement with Laboratorios Clausen, Uruguay for grant of non-exclusive marketing rights of the Company's medicine "Tacrolimus (Pangraph)" for few markets in Europe.
The Company has submitted to BSE a copy of the Press Release in this regard.Read More
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.